HIGHLIGHTS
- who: Daiki Ousaka from the Syntacoll GmbH, Germany University Hospital Wu00fcrzburg have published the Article: Is hemolysis a novel therapeutic target in COVID-19?, in the Journal: (JOURNAL)
- what: In this opinion, the authors focus the attention on hemolysis as a candidate target. The authors focus on the hemolysis in COVID-19 and consider the change in scavenging of hemolysis-related products under severe inflammation and tissue destruction environment.
SUMMARY
Received ACCEPTED CITATION Ousaka D and Nishibori M Is hemolysis a novel therapeutic target in COVID-19? The authors consider possible . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.